REGN congressional trades
Regeneron Pharmaceuticals, Inc. (REGN) appears in 14 congressional disclosure rows from 8 members of Congress in 2025–2026 periodic reports: 5 purchases and 9 sales, with trade dates from Jan 15, 2025 to May 15, 2026. Julie Johnson reported the most, with 3 rows. The median gap between trade date and filing date is 29 days, and 1 trade was reported more than 45 days after it happened.
Rows keep the disclosed owner and amount range. This is a record of reported transactions, not a live REGN portfolio or a trading signal.
- 14
- 8
- 5 / 9
- $28K – $245K
- sum of reported ranges
- 2026-05-15
Verified REGN congressional disclosures
Parsed from official House Clerk and Senate eFD filings. This snapshot contains 5 purchases and 9 sales. Reported owners: Self, Spouse, Joint. Transaction dates run from 2025-01-15 to 2026-05-15.
| Politician | Trade date | Asset | Type | Owner | Amount | Filing |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20034713 Filed 2026-06-08 | |
| Alan Armstrong | Regeneron Pharmaceuticals, Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #fda235b3-bad7-4637-8fa1-053f354d929c Filed 2026-07-21 | |
| Julia Letlow | Regeneron Pharmaceuticals, Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20034106 Filed 2026-03-12 | |
| Gilbert Cisneros | Regeneron Pharmaceuticals, Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20033619 Filed 2025-12-15 | |
| Robert Bresnahan | Regeneron Pharmaceuticals, Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030482 Filed 2025-06-09 | |
| Byron Donalds | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20030342 Filed 2025-05-24 | |
| Byron Donalds | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Spouse | $1,001 - $15,000 | #20030342 Filed 2025-05-24 | |
| Robert Bresnahan | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20030291 Filed 2025-05-08 | |
| Jefferson Shreve | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Self | $15,001 - $50,000 | #20030231 Filed 2025-05-08 | |
| Julie Johnson | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Joint | $1,001 - $15,000 | #20030296 Filed 2025-05-14 | |
| Robert Bresnahan | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20029034 Filed 2025-03-27 | |
| Julie Johnson | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Joint | $1,001 - $15,000 | #20027936 Filed 2025-03-12 | |
| Josh Gottheimer | Regeneron Pharmaceuticals, Inc. - Common Stock | Sale | Joint | $1,001 - $15,000 | #20026732 Filed 2025-02-10 | |
| Julie Johnson | Regeneron Pharmaceuticals, Inc. - Common Stock | Purchase | Joint | $1,001 - $15,000 | #20026762 Filed 2025-02-12 |
A filing can describe the member, a spouse, a dependent, or a joint asset. Amounts are statutory ranges, not execution prices. See how to read congressional stock-trade disclosures before treating a delayed row as a trading signal.
REGN disclosures by member
| Member | Rows | Buys | Sells | Last trade |
|---|---|---|---|---|
| Julie Johnson's REGN trades | 3 | 1 | 2 | 2025-04-01 |
| Robert Bresnahan's REGN trades | 3 | 1 | 2 | 2025-05-15 |
| Byron Donalds | 2 | 0 | 2 | 2025-04-10 |
| Gilbert Cisneros | 2 | 1 | 1 | 2026-05-15 |
| Alan Armstrong | 1 | 1 | 0 | 2026-03-27 |
| Jefferson Shreve | 1 | 0 | 1 | 2025-04-07 |
| Josh Gottheimer | 1 | 0 | 1 | 2025-01-24 |
| Julia Letlow | 1 | 1 | 0 | 2026-02-12 |
How long disclosure took
Days from trade date to filing date for 14 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 0
- 16–30 days
- 9
- 31–45 days
- 4
- Over 45 days
- 1
- Median / longest
- 29d / 116d
Source documents
13 House Clerk and Senate eFD periodic transaction reports, newest first. Each link opens the official filing.
- #fda235b3-bad7-4637-8fa1-053f354d929cFiled 2026-07-21 · 1 row
- #20034713Filed 2026-06-08 · 1 row
- #20034106Filed 2026-03-12 · 1 row
- #20033619Filed 2025-12-15 · 1 row
- #20030482Filed 2025-06-09 · 1 row
- #20030342Filed 2025-05-24 · 2 rows
- #20030296Filed 2025-05-14 · 1 row
- #20030231Filed 2025-05-08 · 1 row
- #20030291Filed 2025-05-08 · 1 row
- #20029034Filed 2025-03-27 · 1 row
- #20027936Filed 2025-03-12 · 1 row
- #20026762Filed 2025-02-12 · 1 row
1 older filings are linked from the transaction table.
What REGN filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- Regeneron Pharmaceuticals, Inc. financials and filings
Audited SEC figures, what moves REGN, and primary sources.
Compare LLY vs REGN side by side
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchRelated research
REGN congressional trades: FAQ
Who in Congress traded REGN?
House Clerk and Senate eFD periodic reports for 2025 and 2026 contain 14 verified REGN rows from 8 members: Alan Armstrong, Byron Donalds, Gilbert Cisneros, Jefferson Shreve, and 4 other members. Image-only filings are excluded, and this is not a live brokerage statement.
Does this page show current REGN holdings?
No. STOCK Act filings disclose reportable transactions after the fact, usually within 45 days, as amount ranges and owners. They do not prove a current position, an exact share count, or why the trade happened.
Why are REGN amounts shown as ranges?
Congressional periodic transaction reports use statutory value bands such as $1,001 - $15,000; $15,001 - $50,000. Yield Theory keeps those ranges instead of inventing a midpoint, exact trade size, or return.
How complete is REGN congressional-trade coverage?
This snapshot covers every machine-readable House and Senate periodic transaction report for 2025 and 2026 (178 members). Image-only House filings and paper Senate filings are not included, so missing rows are not proof that no other lawmaker traded REGN.
Yield Theory is not affiliated with any elected official. This page uses the 2025–2026 House Clerk and Senate eFD periodic report snapshot generated 2026-11-03. It is not a complete lifetime portfolio, a performance track record, or investment advice.
A disclosure is not a thesis.
This page shows who reported REGN and in what range. Membership is the monthly sourced call, plus a five-minute check when the evidence moves. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included